酵素阻害剤の世界市場レポート 2025年

酵素阻害剤の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR4.6％で2,266億5,000万米ドルに成長します。予測期間の成長は、研究開発活動への投資拡大、個別化医療への需要増加、新興国市場での慢性疾患罹患率の上昇、がん治療における酵素阻害剤の需要拡大、希少疾患や遺伝性疾患への応用拡大などに起因すると考えられます。予測期間における主な動向としては、可逆性および不可逆性酵素阻害剤の開発、酵素阻害剤の供給源としての天然物の探索、酵素阻害剤探索における計算手法の統合、個別化投与および治療レジメンの重視、腫瘍学および神経変性疾患における酵素阻害剤応用の拡大などが挙げられます。

がんを含む疾患の発生率の増加は、酵素阻害剤市場の今後の成長を促進すると予想されます。ほとんどの腫瘍細胞で活性を持つテロメラーゼなどの酵素は、白血病を含むがんを治療するために利用され、また健康な成人細胞ががん化するのを防ぎます。例えば、がん撲滅を目指す米国の非営利ヘルスケア団体である米国がん協会によると、2022年1月、米国では毎日平均1,670人ががんで死亡し、190万人ががんと診断され、60万9,360人が死亡するといいます。したがって、がんなどの疾病の発生率の増加が、酵素阻害剤市場の成長需要を牽引しています。

個別化医療に対する需要の高まりが、今後数年間の酵素阻害剤市場の成長を促進すると予想されます。個別化医療は、精密医療とも呼ばれ、DNA、周囲の環境、ライフスタイルにおける各人固有の多様性を考慮した医療・治療方法です。酵素阻害剤は、特定の個人や疾患のサブタイプに合わせて調整できるため、個別化医療における貴重なツールであり、集中治療、精密医療、診断、創薬など、個別化医療における幅広い用途があります。例えば、米国を拠点とする製薬、バイオテクノロジー、診断、IT企業、医療提供者、支払者の非営利団体である個別化医療連合（Personalized Medicine Coalition）によると、2022年には、個別化医療は米国食品医薬品局（FDA）による新薬承認の34%に寄与し、過去8年間はいずれも承認の25%以上を占めていました。したがって、個別化医療に対する需要の高まりが酵素阻害剤市場を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の酵素阻害剤市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の酵素阻害剤市場の成長率分析
• 世界の酵素阻害剤市場の実績：規模と成長、2019～2024年
• 世界の酵素阻害剤市場の予測：規模と成長、2024～2029年、2034年
• 世界の酵素阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の酵素阻害剤市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• プロトンポンプ阻害剤（PPI）
• プロテアーゼ阻害剤
• 逆転写酵素阻害剤
• アロマターゼ阻害剤
• キナーゼ阻害剤
• ノイラミニダーゼ阻害剤
• スタチン
• その他のタイプ
• 世界の酵素阻害剤市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• 慢性閉塞性肺疾患
• 心血管疾患
• 胃腸障害
• 関節炎
• 炎症性疾患
• その他の疾患
• 世界の酵素阻害剤市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 化学療法
• 抗生物質
• 農薬
• 心臓血管治療
• その他の用途
• 世界の酵素阻害剤市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 製薬
• バイオテクノロジー
• 食品・飲料
• その他のエンドユーザー
• 世界の酵素阻害剤市場：プロトンポンプ阻害剤（PPI）のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• オメプラゾール
• エソメプラゾール
• ランソプラゾール
• パントプラゾール
• ラベプラゾール
• 世界の酵素阻害剤市場：プロテアーゼ阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• リトナビル
• ロピナビル
• アタザナビル
• サキナビル
• ダルナビル
• 世界の酵素阻害剤市場：逆転写酵素阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• NRTI（ヌクレオシド逆転写酵素阻害剤）
• NNRTI（非ヌクレオシド系逆転写酵素阻害剤）
• 世界の酵素阻害剤市場：アロマターゼ阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• アナストロゾール
• レトロゾール
• エキセメスタン
• 世界の酵素阻害剤市場：キナーゼ阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• BCR-ABL阻害剤
• EGFR阻害剤
• ALK阻害剤
• MEK阻害剤
• 世界の酵素阻害剤市場：ノイラミニダーゼ阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• オセルタミビル
• ザナミビル
• ペラミビル
• 世界の酵素阻害剤市場：スタチンのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• アトルバスタチン
• シンバスタチン
• ロスバスタチン
• ロバスタチン
• 世界の酵素阻害剤市場：その他のタイプのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 抗葉酸剤
• ホスホジエステラーゼ阻害剤
• シクロオキシゲナーゼ阻害剤

第7章 地域別・国別分析

• 世界の酵素阻害剤市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の酵素阻害剤市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 酵素阻害剤市場：競合情勢
• 酵素阻害剤市場：企業プロファイル
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Pfizer Inc.
• Takeda Pharmaceutical Company
• Merck and Co. Inc.
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Cipla USA Inc.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Janssen Pharmaceuticals
• Acellera Ltd.
• Bioinfogate SL
• BioSolveIT GmbH
• Dassault Systemes BIOVIA Corp.
• ChemAxon Ltd.
• Cheminformatics Tools and Services LLC

第32章 世界市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 市場の最近の動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 酵素阻害剤市場2029年-最も新しい機会を提供する国
• 酵素阻害剤市場2029年-最も新しい機会を提供するセグメント
• 酵素阻害剤市場2029年-成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Enzyme inhibitor refers to a chemical that inhibits an enzyme's activity. Enzymes participate in a variety of cell processes, including cell signaling, growth, and division, as well as accelerating chemical reactions in the body. Enzymes help to speed up chemical reactions in the body and take part in many cell functions, including cell signaling, growth, and division.

The main types of enzyme inhibitors are proton pump inhibitors (PPIs), protease inhibitors, reverse transcriptase inhibitors, aromatase inhibitors, kinase inhibitors, neuraminidase inhibitors, statins, and other types. Proton pump inhibitors refer to medicines that work by decreasing the amount of stomach acid made by glands in the lining of the stomach. The various disease indications include chronic obstructive pulmonary disorders, cardiovascular disease, gastrointestinal disorders, arthritis, inflammatory diseases, and others. The enzyme inhibitors are applicable in chemotherapy, antibiotics, pesticides, cardiovascular treatments, and others and are used in pharmaceuticals, biotechnology, food and beverage, and other end users.

The enzyme inhibitors market research report is one of a series of new reports from The Business Research Company that provides enzyme inhibitors market statistics, including enzyme inhibitors industry global market size, regional shares, competitors with an enzyme inhibitors market share, detailed enzyme inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the enzyme inhibitors industry. This enzyme inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The enzyme inhibitor market size has grown steadily in recent years. It will grow from $183.8 billion in 2024 to $189.26 billion in 2025 at a compound annual growth rate (CAGR) of 3.0%. The growth in the historic period can be attributed to increased demand for enzyme inhibitors inThe treatment of various diseases, advancements in drug discovery and development, growing prevalence of chronic diseases, increased geriatric population, rising awareness aboutThe benefits of enzyme inhibitors.

The enzyme inhibitor market size is expected to see steady growth in the next few years. It will grow to $226.65 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to growing investment in research and development activities, increasing demand for personalized medicine, rising incidence of chronic diseases in emerging markets, growing demand for enzyme inhibitors in the treatment of cancer, expansion of applications in rare and genetic diseases. Major trends in the forecast period include development of reversible and irreversible enzyme inhibitors, exploration of natural products as sources of enzyme inhibitors, integration of computational methods in enzyme inhibitor discovery, emphasis on personalized dosing and treatment regimens, expansion of enzyme inhibitor applications in oncology and neurodegenerative diseases.

The rise in the incidence of diseases including cancer is expected to propel the growth of the enzyme inhibitor market going forward. Enzymes, such as telomerase, which is active in most tumor cells, are utilized to cure cancers, including leukemia, and also keep healthy adult cells from becoming cancerous. For instance, in January 2022, according to the American Cancer Society, a US-based non-profit healthcare group dedicated to cancer elimination, on average in the US, 1,670 individuals are going to die from cancer every day in 2022, with 1. 9 million cases being diagnosed and 609,360 fatalities. Therefore, the rise in the incidence of diseases such as cancer is driving the demand for the enzyme inhibitor market growth.

The increasing demand for personalized medicine is expected to propel the growth of the enzyme inhibitor market in the coming years. Personalized medicine, additionally referred to as precision medicine, is a health care and treatment method that considers each person's specific diversity in DNA, surroundings, and lifestyle. Enzyme inhibitors are a valuable tool in personalized medicine because they can be adjusted to particular individuals or disease subtypes and have a wide range of applications in personalized medicine, including focused therapy, precision medicine, diagnostics, and drug discovery. For instance, in 2022, according to the Personalized Medicine Coalition, a US-based nonprofit umbrella association for pharmaceuticals, biotechnology, diagnosis, and information technology firms, as well as healthcare providers and payers, personalized medications contributed to 34% of new drug approvals by the US Food and Drug Administration and had been responsible for at least 25% of approvals in each of the previous eight years. Therefore, the increasing demand for personalized medicine is driving the enzyme inhibitor market.

Leading companies in the enzyme inhibitor market are prioritizing innovative therapies, such as selective kinase inhibitors, to enhance treatment options and improve patient outcomes across various diseases. Jaypirca (pirtobrutinib) is a highly selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor approved by the FDA for treating adult patients with relapsed or refractory mantle cell lymphoma after at least two prior systemic treatments. For example, in January 2023, Loxo Oncology at Lilly, the oncology division of Eli Lilly and Company, a U.S.-based pharmaceutical firm, introduced Jaypirca tablets. It is the first and only non-covalent (reversible) BTK inhibitor approved by the Food and Drug Administration (FDA), a U.S.-based health organization. This approval marks a major breakthrough for patients with mantle cell lymphoma (MCL) who have exhausted current treatment options. Jaypirca offers a novel approach to targeting the BTK pathway, potentially improving outcomes for this patient group.

Major companies operating in the enzyme inhibitor market are focusing on developing innovative products, such as Sotyktu, to better meet the needs of their existing consumers. Sotyktu is an allosteric tyrosine kinase 2 (TYK2) inhibitor drug intended to inhibit or limit the activity of the TYK2 enzyme by attaching to a location on the enzyme other than its active site. For instance, in September 2022, Bristol-Myers Squibb Company, a US-based pharmaceutical firm, announced the approval of Sotyktu, a selective oral allosteric tyrosine kinase 2 (TYK2) inhibitor that is the first of its kind by the U. S. Food and Drug Administration. Sotyktu is a prescription medication authorized for treating people with moderate-to-severe plaque psoriasis who are not candidates for systemic therapy or phototherapy. 1,2 Sotyktu should not be used in conjunction with other strong immunosuppressants. Sotyktu can serve as the new standard of care for oral therapy for persons with moderate-to-severe plaque psoriasis due to its track record of assisting patients in attaining smoother skin in the POETYK PSO clinical study.

In August 2024, Eli Lilly and Company, a U.S.-based pharmaceutical firm, acquired Morphic Holding, Inc. for an undisclosed sum. Through this acquisition, Eli Lilly seeks to expand its therapeutic portfolio in gastroenterology, drive innovation in treatment options for inflammatory bowel disease, bolster its market presence, capitalize on research synergies, and increase patient access to effective therapies. Morphic Holding Inc. is a U.S.-based biopharmaceutical company focused on developing enzyme inhibitors.

Major companies operating in the enzyme inhibitor market include Abbott Laboratories, Amgen Inc., AstraZeneca plc, Bayer AG, F. Hoffmann-La Roche AG, Pfizer Inc., Takeda Pharmaceutical Company, Merck and Co. Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Cipla USA Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals, Acellera Ltd., Bioinfogate SL, BioSolveIT GmbH, Dassault Systemes BIOVIA Corp., ChemAxon Ltd., Cheminformatics Tools and Services LLC, Cresset BioMolecular Discovery Ltd., Dotmatics Limited, Enamine Ltd., Forge Therapeutics Inc., Inte:Ligand GmbH, LeadIT, Molecular Forecaster Inc., Chemical Computing Group Inc., OpenEye Scientific Software Inc.

North America was the largest region in the enzyme inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the enzyme inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the enzyme inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The enzyme inhibitor market consists of sales of competitive, noncompetitive, and uncompetitive inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Enzyme Inhibitor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on enzyme inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for enzyme inhibitor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The enzyme inhibitor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Proton Pump Inhibitors (PPIs); Protease Inhibitors; Reverse Transcriptase Inhibitors; Aromatase Inhibitors; Kinase Inhibitors; Neuraminidase Inhibitors; Statins; Other Types
• 2) By Disease Indication: Chronic Obstructive Pulmonary Disorders; Cardiovascular Disease; Gastrointestinal Disorders; Arthritis; Inflammatory Diseases; Other Disease Indications
• 3) By Application: Chemotherapy; Antibiotics; Pesticides; Cardiovascular Treatments; Other Applications
• 4) By End User: Pharmaceutical; Biotechnology; Food And Beverage; Other End Users
• Subsegments:
• 1) By Proton Pump Inhibitors (PPIs): Omeprazole; Esomeprazole; Lansoprazole; Pantoprazole; Rabeprazole
• 2) By Protease Inhibitors: Ritonavir; Lopinavir; Atazanavir; Saquinavir; Darunavir
• 3) By Reverse Transcriptase Inhibitors: NRTIs (Nucleoside Reverse Transcriptase Inhibitors); NNRTIs (Non-Nucleoside Reverse Transcriptase Inhibitors)
• 4) By Aromatase Inhibitors: Anastrozole; Letrozole; Exemestane
• 5) By Kinase Inhibitors: BCR-ABL Inhibitors; EGFR Inhibitors; ALK Inhibitors; MEK Inhibitors
• 6) By Neuraminidase Inhibitors: Oseltamivir; Zanamivir; Peramivir
• 7) By Statins: Atorvastatin; Simvastatin; Rosuvastatin; Lovastatin
• 8) By Other Types: Antifolates; Phosphodiesterase Inhibitors; Cyclooxygenase Inhibitors
• Companies Mentioned: Abbott Laboratories; Amgen Inc.; AstraZeneca plc; Bayer AG; F. Hoffmann-La Roche AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Enzyme Inhibitor Market Characteristics

3. Enzyme Inhibitor Market Trends And Strategies

4. Enzyme Inhibitor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Enzyme Inhibitor Growth Analysis And Strategic Analysis Framework

• 5.1. Global Enzyme Inhibitor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Enzyme Inhibitor Market Growth Rate Analysis
• 5.4. Global Enzyme Inhibitor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Enzyme Inhibitor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Enzyme Inhibitor Total Addressable Market (TAM)

6. Enzyme Inhibitor Market Segmentation

• 6.1. Global Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Proton Pump Inhibitors (PPIs)
• Protease Inhibitors
• Reverse Transcriptase Inhibitors
• Aromatase Inhibitors
• Kinase Inhibitors
• Neuraminidase Inhibitors
• Statins
• Other Types
• 6.2. Global Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Obstructive Pulmonary Disorders
• Cardiovascular Disease
• Gastrointestinal Disorders
• Arthritis
• Inflammatory Diseases
• Other Disease Indications
• 6.3. Global Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Antibiotics
• Pesticides
• Cardiovascular Treatments
• Other Applications
• 6.4. Global Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmaceutical
• Biotechnology
• Food and Beverage
• Other End Users
• 6.5. Global Enzyme Inhibitor Market, Sub-Segmentation Of Proton Pump Inhibitors (PPIs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Omeprazole
• Esomeprazole
• Lansoprazole
• Pantoprazole
• Rabeprazole
• 6.6. Global Enzyme Inhibitor Market, Sub-Segmentation Of Protease Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ritonavir
• Lopinavir
• Atazanavir
• Saquinavir
• Darunavir
• 6.7. Global Enzyme Inhibitor Market, Sub-Segmentation Of Reverse Transcriptase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• NRTIs (Nucleoside Reverse Transcriptase Inhibitors)
• NNRTIs (Non-Nucleoside Reverse Transcriptase Inhibitors)
• 6.8. Global Enzyme Inhibitor Market, Sub-Segmentation Of Aromatase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anastrozole
• Letrozole
• Exemestane
• 6.9. Global Enzyme Inhibitor Market, Sub-Segmentation Of Kinase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• BCR-ABL Inhibitors
• EGFR Inhibitors
• ALK Inhibitors
• MEK Inhibitors
• 6.10. Global Enzyme Inhibitor Market, Sub-Segmentation Of Neuraminidase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oseltamivir
• Zanamivir
• Peramivir
• 6.11. Global Enzyme Inhibitor Market, Sub-Segmentation Of Statins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atorvastatin
• Simvastatin
• Rosuvastatin
• Lovastatin
• 6.12. Global Enzyme Inhibitor Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antifolates
• Phosphodiesterase Inhibitors
• Cyclooxygenase Inhibitors

7. Enzyme Inhibitor Market Regional And Country Analysis

• 7.1. Global Enzyme Inhibitor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Enzyme Inhibitor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Enzyme Inhibitor Market

• 8.1. Asia-Pacific Enzyme Inhibitor Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Enzyme Inhibitor Market

• 9.1. China Enzyme Inhibitor Market Overview
• 9.2. China Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Enzyme Inhibitor Market

• 10.1. India Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Enzyme Inhibitor Market

• 11.1. Japan Enzyme Inhibitor Market Overview
• 11.2. Japan Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Enzyme Inhibitor Market

• 12.1. Australia Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Enzyme Inhibitor Market

• 13.1. Indonesia Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Enzyme Inhibitor Market

• 14.1. South Korea Enzyme Inhibitor Market Overview
• 14.2. South Korea Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Enzyme Inhibitor Market

• 15.1. Western Europe Enzyme Inhibitor Market Overview
• 15.2. Western Europe Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Enzyme Inhibitor Market

• 16.1. UK Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Enzyme Inhibitor Market

• 17.1. Germany Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Enzyme Inhibitor Market

• 18.1. France Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Enzyme Inhibitor Market

• 19.1. Italy Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Enzyme Inhibitor Market

• 20.1. Spain Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Enzyme Inhibitor Market

• 21.1. Eastern Europe Enzyme Inhibitor Market Overview
• 21.2. Eastern Europe Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Enzyme Inhibitor Market

• 22.1. Russia Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Enzyme Inhibitor Market

• 23.1. North America Enzyme Inhibitor Market Overview
• 23.2. North America Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Enzyme Inhibitor Market

• 24.1. USA Enzyme Inhibitor Market Overview
• 24.2. USA Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Enzyme Inhibitor Market

• 25.1. Canada Enzyme Inhibitor Market Overview
• 25.2. Canada Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Enzyme Inhibitor Market

• 26.1. South America Enzyme Inhibitor Market Overview
• 26.2. South America Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Enzyme Inhibitor Market

• 27.1. Brazil Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Enzyme Inhibitor Market

• 28.1. Middle East Enzyme Inhibitor Market Overview
• 28.2. Middle East Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Enzyme Inhibitor Market

• 29.1. Africa Enzyme Inhibitor Market Overview
• 29.2. Africa Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Enzyme Inhibitor Market Competitive Landscape And Company Profiles

• 30.1. Enzyme Inhibitor Market Competitive Landscape
• 30.2. Enzyme Inhibitor Market Company Profiles
  • 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

31. Enzyme Inhibitor Market Other Major And Innovative Companies

• 31.1. Pfizer Inc.
• 31.2. Takeda Pharmaceutical Company
• 31.3. Merck and Co. Inc.
• 31.4. Eli Lilly and Company
• 31.5. Bristol-Myers Squibb Company
• 31.6. Cipla USA Inc.
• 31.7. AbbVie Inc.
• 31.8. Teva Pharmaceutical Industries Ltd.
• 31.9. Janssen Pharmaceuticals
• 31.10. Acellera Ltd.
• 31.11. Bioinfogate SL
• 31.12. BioSolveIT GmbH
• 31.13. Dassault Systemes BIOVIA Corp.
• 31.14. ChemAxon Ltd.
• 31.15. Cheminformatics Tools and Services LLC

32. Global Enzyme Inhibitor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Enzyme Inhibitor Market

34. Recent Developments In The Enzyme Inhibitor Market

35. Enzyme Inhibitor Market High Potential Countries, Segments and Strategies

• 35.1 Enzyme Inhibitor Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Enzyme Inhibitor Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Enzyme Inhibitor Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer